|
AU2012244213A1
|
|
Oncofetal fibronectin as a marker for disease and other conditions and methods for detection of oncofetal fibronectin
|
|
WO2006026020A2
|
|
Oncofetal fibronectin as a marker for disease and other conditions and methods for detection of oncofetal fibronectin
|
|
CA2512989A1
|
|
Screening and treatment methods for prevention of preterm delivery
|
|
US6394952B1
|
|
Point of care diagnostic systems
|
|
US6267722B1
|
|
Point of care diagnostic systems
|
|
US6678669B2
|
|
Method for selecting medical and biochemical diagnostic tests using neural network-related applications
|
|
WO9729447A2
|
|
Method for selecting medical and biochemical diagnostic tests using neural network-related applications
|
|
WO9626273A1
|
|
Polypeptides derived from urinastatin having calcium channel blocking activity and their use to delay premature delivery
|
|
US5516702A
|
|
Screening method for identifying women at increased risk for imminent delivery
|
|
WO9417405A1
|
|
Assay method to rule out rupture of membranes in women at risk for imminent delivery
|
|
WO9324838A1
|
|
Screening method for identifying women at increased risk for preterm delivery
|
|
WO9324836A1
|
|
Screening method for identifying women at increased risk for preterm delivery
|
|
WO9309432A1
|
|
Screening method for identifying women at increased risk for imminent delivery
|
|
WO9309438A1
|
|
Screening method for identifying women at increased risk for preterm delivery
|
|
US5236846A
|
|
Ectopic pregnancy test
|
|
IL98150D0
|
|
Highly reflective biogratings and method for theirhighly reflective biogratings and method production
|
|
AU7674591A
|
|
Pregnancy induced hypertension and eclampsia immunoassay and reagents
|
|
US5281522A
|
|
Reagents and kits for determination of fetal fibronectin in a vaginal sample
|
|
CA2011704A1
|
|
Endometriosis diagnosis methods and reagents
|
|
IE900795L
|
|
Endometriosis diagnosis methods and reagents
|
